Detalhe da pesquisa
1.
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Invest New Drugs
; 31(3): 696-706, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22886613
2.
The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Methods
; 52(4): 301-6, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20801221
3.
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.
Blood Adv
; 3(5): 797-812, 2019 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30850386
4.
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Clin Cancer Res
; 16(22): 5564-72, 2010 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20926400